Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given an average recommendation of “Moderate Buy” by the five analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $43.80.

A number of equities analysts have issued reports on the stock. Royal Bank of Canada decreased their price objective on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Oppenheimer reduced their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, July 15th.

Inovio Pharmaceuticals Stock Performance

INO opened at $5.60 on Wednesday. Inovio Pharmaceuticals has a 1 year low of $3.89 and a 1 year high of $14.75. The stock’s 50 day simple moving average is $6.30 and its 200 day simple moving average is $8.71.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million. During the same quarter last year, the firm posted ($1.56) earnings per share. Analysts expect that Inovio Pharmaceuticals will post -4.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of INO. SG Americas Securities LLC purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $71,000. The Manufacturers Life Insurance Company bought a new position in Inovio Pharmaceuticals in the second quarter worth $82,000. Dimensional Fund Advisors LP purchased a new position in Inovio Pharmaceuticals during the second quarter valued at $605,000. Cornercap Investment Counsel Inc. bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $184,000. Finally, American Century Companies Inc. grew its position in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares during the period. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.